Epigenetic age acceleration among survivors of pediatric medulloblastoma and primitive neuroectodermal tumor. (19th May 2023)

• Record Type: Journal Article
• Authors: Harris, Rachel D.; Richard, Melissa A.; Gramatges, Maria Monica J.; Wilhelm, Kevin; Scheurer, Michael E.; Lupo, Philip J.; Brown, Austin L.
• Is Part Of: Pediatric hematology and oncology. Volume 40:Number 4(2023)
• Page Start: 407
• Page End: 411
• Publication Date: 2023-05-19
• Subjects: Epigenetics -- aging -- survivorship -- PNET -- medulloblastoma; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2022.2101722
• Languages: English
• ISSNs: 0888-0018

Abstract

Abstract: Survivors of childhood central nervous system (CNS) tumors experience early-onset aging-related phenotypes. DNA methylation (DNAm) age is an emerging epigenetic biomarker of physiologic age and may be predictive of chronic health conditions in long-term survivors. This report describes the course of epigenetic age acceleration using post-diagnosis blood samples (median: 3.9 years post-diagnosis; range: 0.04-15.96) from 83 survivors of pediatric CNS tumors. Epigenetic age acceleration was detected in 72% of patients, with an average difference between chronologic and DNAm age of 2.58 years (95% CI: 1.75-3.41, p < 0.001). Time from diagnosis to sample collection correlated with the magnitude of epigenetic age acceleration.